Evaluating 2B3, a novel immunotherapy in PDAPP model of amyloid pathology
There are currently no disease-modifying therapies to halt or prevent the onset of Alzheimer’s disease (AD). Immunotherapy and antibodies targeting the neurotoxic amyloid-β (Aβ) peptide for its removal from the brain have provided a promising opportunity to provide disease-modifying therapies. Howev...
| Main Author: | |
|---|---|
| Published: |
Cardiff University
2016
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.699359 |